Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
01:01pm, Wednesday, 25'th Mar 2026
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
02:00am, Tuesday, 24'th Mar 2026
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo
Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Nordea Investment Management AB Acquires 74,350 Shares of Regeneron Pharmaceuticals, Inc. $REGN
05:51am, Monday, 23'rd Mar 2026
Nordea Investment Management AB boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 118.1% during the fourth quarter, according to the company in its most recent filing wi
California Public Employees Retirement System Sells 111,602 Shares of Regeneron Pharmaceuticals, Inc. $REGN
04:50am, Tuesday, 17'th Mar 2026
California Public Employees Retirement System lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 35.5% in the undefined quarter, according to its most recent 13F filin
Alliancebernstein L.P. Sells 63,344 Shares of Regeneron Pharmaceuticals, Inc. $REGN
03:21am, Monday, 16'th Mar 2026
Alliancebernstein L.P. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 10.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Excha
Game Creek Capital LP Has $2.77 Million Position in Regeneron Pharmaceuticals, Inc. $REGN
03:50am, Saturday, 14'th Mar 2026
Game Creek Capital LP boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 60.2% during the third quarter, according to the company in its most recent filing with the Secur
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of “Moderate Buy” from Analysts
02:44am, Saturday, 14'th Mar 2026
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-six analysts that are presently covering the company, Marke
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
03:44am, Thursday, 12'th Mar 2026
Regeneron's shares are positioned to rise, thanks to the performance of its pipeline. Its top-selling drug, Dupixent, has already been approved for nine indications.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
01:52pm, Wednesday, 11'th Mar 2026
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Regeneron: Fairly Valued Now After A Stellar Upswing
09:47am, Wednesday, 11'th Mar 2026
Regeneron Pharmaceuticals, Inc. is rated a long-term Buy, but I expect near-term sideways trading due to limited new catalysts. Declining Eylea/Eylea HD revenues are largely offset by strong Dupixent
Regeneron and Society for Science announced that Connor Hill, 17, of State College, PA, won the top $250,000 award in the Regeneron Science Talent Search
Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Srs. for Innovative Research
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
11:20am, Tuesday, 10'th Mar 2026
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
2 Underrated Weight Loss Stocks to Buy Now
08:00am, Sunday, 08'th Mar 2026
Regeneron has a pair of weight-loss candidates close to entering late-stage studies. Roche's recent mid-stage readout positions it as a strong contender in the weight loss market.
